Current and historical daily PE Ratio for Alk-Abello A/S (
) from 2009 to Jun 07 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Alk-Abello A/S stock (AKBLF) PE ratio as of Jun 07 2024 is 56.32.
More Details
Alk-Abello A/S (AKBLF) PE Ratio (TTM) Chart
Alk-Abello A/S (AKBLF) PE Ratio (TTM) Historical Data
View and export this data going back to 2009. Start your Free Trial
Total 1243
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Alk-Abello A/S PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-07 | 56.3 | 2024-04-04 | 50.5 |
| 2024-06-06 | 56.3 | 2024-04-03 | 50.5 |
| 2024-06-05 | 56.3 | 2024-04-02 | 50.5 |
| 2024-06-04 | 58.1 | 2024-04-01 | 50.5 |
| 2024-06-03 | 61.8 | 2024-03-28 | 50.5 |
| 2024-05-31 | 61.8 | 2024-03-27 | 60.3 |
| 2024-05-30 | 61.8 | 2024-03-26 | 60.7 |
| 2024-05-29 | 49.2 | 2024-03-25 | 60.7 |
| 2024-05-28 | 49.2 | 2024-03-22 | 60.7 |
| 2024-05-24 | 49.2 | 2024-03-21 | 60.7 |
| 2024-05-23 | 49.2 | 2024-03-20 | 60.7 |
| 2024-05-22 | 49.2 | 2024-03-19 | 60.7 |
| 2024-05-21 | 49.2 | 2024-03-18 | 60.7 |
| 2024-05-20 | 49.2 | 2024-03-15 | 60.7 |
| 2024-05-17 | 49.2 | 2024-03-14 | 60.7 |
| 2024-05-16 | 49.2 | 2024-03-13 | 60.7 |
| 2024-05-15 | 49.2 | 2024-03-12 | 60.7 |
| 2024-05-14 | 49.2 | 2024-03-11 | 60.7 |
| 2024-05-13 | 49.2 | 2024-03-08 | 60.7 |
| 2024-05-10 | 49.2 | 2024-03-07 | 60.7 |
| 2024-05-09 | 49.2 | 2024-03-06 | 60.7 |
| 2024-05-08 | 49.2 | 2024-03-05 | 60.7 |
| 2024-05-07 | 49.2 | 2024-03-04 | 60.7 |
| 2024-05-06 | 49.2 | 2024-03-01 | 60.7 |
| 2024-05-03 | 49.2 | 2024-02-29 | 60.7 |
| 2024-05-02 | 49.2 | 2024-02-28 | 60.7 |
| 2024-05-01 | 49.2 | 2024-02-27 | 60.7 |
| 2024-04-30 | 49.2 | 2024-02-26 | 60.7 |
| 2024-04-29 | 49.2 | 2024-02-23 | 60.7 |
| 2024-04-26 | 49.2 | 2024-02-22 | 60.7 |
| 2024-04-25 | 49.2 | 2024-02-21 | 60.7 |
| 2024-04-24 | 49.2 | 2024-02-20 | 60.7 |
| 2024-04-23 | 49.2 | 2024-02-16 | 43.4 |
| 2024-04-22 | 49.2 | 2024-02-15 | 43.4 |
| 2024-04-19 | 49.2 | 2024-02-14 | 43.4 |
| 2024-04-18 | 51.2 | 2024-02-13 | 43.4 |
| 2024-04-17 | 51.2 | 2024-02-12 | 43.4 |
| 2024-04-16 | 51.2 | 2024-02-09 | 43.4 |
| 2024-04-15 | 51.2 | 2024-02-08 | 43.4 |
| 2024-04-12 | 50.5 | 2024-02-07 | 43.4 |
| 2024-04-11 | 50.5 | 2024-02-06 | 43.4 |
| 2024-04-10 | 50.5 | 2024-02-05 | 43.4 |
| 2024-04-09 | 50.5 | 2024-02-02 | 43.4 |
| 2024-04-08 | 50.5 | 2024-02-01 | 43.4 |
| 2024-04-05 | 50.5 | 2024-01-31 | 43.4 |
Alk-Abello A/S (AKBLF) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Alk-Abello A/S
NAICS : 325412
SIC : 2834
ISIN : DK0061802139
Share Class Description:
AKBLF: Class BCompare
Compare
Traded in other countries / regions
ALK B.Denmark0OIR.UKAKBLF.USA4AJ0.Germany IPO Date
2009-11-16Description
Alk-Abello A/S is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers